Tie-2 ligand 1

{
  "publication_number": "US5879672A",
  "country": "US",
  "kind": "A",
  "title": "Tie-2 ligand 1",
  "abstract": "The present invention provides for an isolated nucleic acid molecule encoding human TIE-2 ligand. In addition, the invention provides for a receptor body which specifically binds human TIE-2 ligand. The invention also provides an antibody which specifically binds human TIE-2 ligand. The invention further provides for therapeutic compositions as well as a method of blocking blood vessel growth, a method of promoting neovascularization and a method of promoting the growth or differentiation of a cell expressing the TIE-2 receptor.",
  "claims": [
    "1. Isolated human TIE-2 ligand 1 encoded by a nucleotide sequence comprising the nucleotide sequence as set forth in FIG. 4 (SEQ. I.D. NO. 1).",
    "2. A composition comprising the ligand of claim 1, and a pharmaceutically acceptable vehicle.",
    "3. The composition of claim 2, wherein the ligand has a cytotoxic agent conjugated thereto.",
    "4. The composition of claim 3, wherein the cytotoxic agent is a radioisotope or toxin.",
    "5. Isolated human TIE-2 ligand 1 comprising the amino acid sequence as set forth in FIG. 4 (SEQ. I.D. NO. 2).",
    "6. A composition comprising the ligand of claim 5, and a pharmaceutically acceptable vehicle.",
    "7. The composition of claim 6, wherein the ligand has a cytotoxic agent conjugated thereto.",
    "8. The composition of claim 7, wherein the cytotoxic agent is a radioisotope or toxin.",
    "9. Isolated human TIE-2 ligand 1 encoded by a nucleotide sequence comprising the nucleotide sequence as set forth in FIG. 5 (SEQ. I.D. NO. 3).",
    "10. A composition comprising the ligand of claim 9, and a pharmaceutically acceptable vehicle.",
    "11. The composition of claim 10, wherein the ligand has a cytotoxic agent conjugated thereto.",
    "12. The composition of claim 11, wherein the cytotoxic agent is a radioisotope or toxin.",
    "13. Isolated human TIE-2 ligand 1 comprising the amino acid sequence as set forth in FIG. 5 (SEQ. I.D. NO. 4).",
    "14. A composition comprising the ligand of claim 13, and a pharmaceutically acceptable vehicle.",
    "15. The composition of claim 14, wherein the ligand has a cytotoxic agent conjugated thereto.",
    "16. The composition of claim 15, wherein the cytotoxic agent is a radioisotope or toxin."
  ],
  "cpc": [
    "C07K 14/515",
    "A61K 38/00",
    "A61P 43/00",
    "C07K 2319/00"
  ],
  "assignees": [
    "REGENERON PHARMA"
  ],
  "filing_date": "1994-12-02",
  "publication_date": "1999-03-09",
  "grant_date": "1999-03-09",
  "priority_date": "1994-10-07",
  "application_number": "US-34849294-A",
  "family_id": "26982203"
}